Songkai Yan

7PUBLICATIONS
19CO-AUTHORS
Medical devicesHaematologyEpidemiological methodsGene and molecular therapyInfant and child health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 04, 2026
Cost-effectiveness of etranacogene dezaparvovec compared to eftrenonacog alfa for the treatment of adult patients with severe and moderately severe haemophilia B in Sweden.

|Sep 18, 2025
Comparing Real-World Outcomes of Prophylaxis with Extended Half-life Factor IX (rIX-FP vs. rFIXFc and N9-GP) for Haemophilia B: An Analysis of Medical Chart Data from Germany.

Martin Olivieri, Songkai Yan, Ying Yang

|Jul 23, 2025
Real-World Prophylaxis Outcomes with rIX-FP and rFIXFc for Males with Hemophilia B: Pooled Analysis of Medical Chart Data from Germany and Italy.

Johannes Oldenburg, Martin Olivieri, Songkai Yan

|Jul 18, 2025
Budget impact analysis of Haemate-P as long-term prophylaxis and on-demand therapy for von Willebrand disease in Spain.

Michele R Wilson, Pablo Mendez, Cheryl L McDade

|Mar 07, 2025
Cost-effectiveness and cost-utility analysis of Haemate-P versus other von Willebrand disease treatments in Spain.

Juan E Megias-Vericat, Gines Escolar, Michele R Wilson

|Oct 30, 2023
Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half-life factor IX therapies for severe or moderately severe haemophilia B.

Robert Klamroth, Ashley Bonner, Keith Gomez

Pageof 2

Frequent Collaborators

3 joint publications

Douglass Drelich

2 joint publications

Juan E Megias-Vericat

2 joint publications

Michele R Wilson

2 joint publications

Cheryl L McDade